{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:37:10Z","timestamp":1740141430148,"version":"3.37.3"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Leverhulme Fellowship","award":["RF-2015-88"],"award-info":[{"award-number":["RF-2015-88"]}]},{"name":"Special Visiting Fellowship","award":["30098\/2014\/7"],"award-info":[{"award-number":["30098\/2014\/7"]}]},{"DOI":"10.13039\/501100006506","name":"Brazilian Ministry of Health","doi-asserted-by":"publisher","award":["777588\/2012"],"award-info":[{"award-number":["777588\/2012"]}],"id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this paper, we study a single serotype transmission model of dengue to determine the optimal vaccination age for Dengvaxia. The transmission dynamics are modelled with an age-dependent force of infection. The force of infection for each serotype is derived from the serological profile of dengue in Brazil without serotype distinction and from serotype-specific reported cases. The risk due to an infection is measured by the probability of requiring hospitalization based on Brazilian Ministry of Health data. The optimal vaccination age is determined for any number and combination of the four distinct dengue virus serotypes DENv1\u20134. The lifetime expected risk is adapted to include antibody dependent enhancement (ADE) and permanent cross-immunity after two heterologous infections. The risk is assumed to be serostatus-dependent. The optimal vaccination age is computed for constant, serostatus-specific vaccine efficacies. Additionally, the vaccination age is restricted to conform to the licence of Dengvaxia in Brazil and the achievable and minimal lifetime expected risks are compared. The optimal vaccination age obtained for the risk of hospitalization varies significantly with the assumptions relating to ADE and cross-immunity. Risk-free primary infections lead to higher optimal vaccination ages, as do asymptomatic third and fourth infections. Sometimes vaccination is not recommended at all, e.g. for any endemic area with a single serotype if primary infections are risk-free. Restricting the vaccination age to Dengvaxia licensed ages mostly leads to only a slightly higher lifetime expected risk and the vaccine should be administered as close as possible to the optimal vaccination age.<\/jats:p>","DOI":"10.1093\/imammb\/dqaa007","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T11:09:25Z","timestamp":1591700965000},"page":"1-27","source":"Crossref","is-referenced-by-count":0,"title":["The optimal age of vaccination against dengue in Brazil based on serotype-specific forces of infection derived from serological data"],"prefix":"10.1093","volume":"38","author":[{"given":"Sandra B","family":"Maier","sequence":"first","affiliation":[{"name":"Department of Mathematics and Statistics, University of Strathclyde, Glasgow G1 1XH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Massad","sequence":"additional","affiliation":[{"name":"School of Applied Mathematics, Fundacao Getulio Vargas, Rio de Janeiro, Brazil, LIM01-Hospital de Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Amaku","sequence":"additional","affiliation":[{"name":"LIM01-Hospital de Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo N","family":"Burattini","sequence":"additional","affiliation":[{"name":"LIM01-Hospital de Cl\u00ednicas, Faculdade de Medicina, Universidade de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil, Hospital S\u00e3o Paulo, Escola Paulista de Medicina, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo, SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Greenhalgh","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, University of Strathclyde, Glasgow G1 1XH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"2021022305195385700_ref1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005179","article-title":"The impact of the newly licensed dengue vaccine in endemic countries","volume":"10","author":"Aguiar","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2021022305195385700_ref2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1473-3099(17)30752-1","article-title":"Dengvaxia: age as a surrogate for serostatus","volume":"18","author":"Aguiar","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"2021022305195385700_ref3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/cid\/cix882","article-title":"Dengvaxia efficacy dependency on serostatus: a closer look at more recent data","volume":"66","author":"Aguiar","year":"2018","journal-title":"Clin. Inf. Dis."},{"key":"2021022305195385700_ref4","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1473-3099(16)30168-2","article-title":"The risks behind Dengvaxia recommendation","volume":"16","author":"Aguiar","year":"2016","journal-title":"Lancet Infect. Dis"},{"key":"2021022305195385700_ref5","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1590\/S0036-46652012000700008","article-title":"Designing a vaccination strategy against dengue","volume":"54","author":"Amaku","year":"2012","journal-title":"Rev. Institut. Med. Trop Sao Paulo"},{"key":"2021022305195385700_ref6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/imammb\/1.3.233","article-title":"Spatial, temporal and genetic heterogeneity in host populations and the design of immunisation programs","volume":"1","author":"Anderson","year":"1984","journal-title":"IMA J. Math. Appl. Med. Biol."},{"key":"2021022305195385700_ref7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1017\/S002217240006160X","article-title":"Age-related changes in the rate of disease transmission: implications for the design of vaccination programs","volume":"94","author":"Anderson","year":"1985","journal-title":"Cambridge J. Hyg."},{"key":"2021022305195385700_ref8","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198545996.001.0001","volume-title":"Infectious Diseases of Humans: Dynamics and Control","author":"Anderson","year":"1991"},{"key":"2021022305195385700_ref9","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"volume-title":"Unpublished serological data","year":"2017","author":"Burattini","key":"2021022305195385700_ref10"},{"volume-title":"Unpublished serological data","year":"2019","author":"Burattini","key":"2021022305195385700_ref11"},{"key":"2021022305195385700_ref12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.6061\/clinics\/2016(08)08","article-title":"Age and regional differences in clinical presentation and risk of hospitalization for dengue in Brazil, 2000\u20132014","volume":"71","author":"Burattini","year":"2016","journal-title":"Clinics"},{"key":"2021022305195385700_ref13","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"2021022305195385700_ref14","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1086\/648407","article-title":"Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants","volume":"200","author":"Chau","year":"2009","journal-title":"J. Inf. Dis."},{"key":"2021022305195385700_ref15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jclinepi.2017.11.019","article-title":"Controversy and debate on dengue vaccine series-paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs","volume":"95","author":"Dans","year":"2018","journal-title":"J. Clin. Epidemiol."},{"key":"2021022305195385700_ref16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1590\/1980-5497201700050017","article-title":"Increase in the burden of dengue in Brazil and federated units, 2000 and 2015: analysis of the Global Burden of Disease Study 2015","volume":"20","author":"de Ar\u00fajo","year":"2017","journal-title":"Rev. Bras. Epidemiol."},{"key":"2021022305195385700_ref17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bjm.2016.10.008","article-title":"Mosquito-transmitted viruses\u2014the great Brazilian challenge","volume":"47","author":"de Oliveira Mota","year":"2016","journal-title":"Braz. J. Microbiol."},{"key":"2021022305195385700_ref18","first-page":"321873","article-title":"Epidemiological scenario of dengue in Brazil","volume":"2015","author":"Fares","year":"2015","journal-title":"Biomed Res. Int."},{"key":"2021022305195385700_ref19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/sim.4780090811","article-title":"Modelling forces of infection for measles, mumps and rubella","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat. Med."},{"key":"2021022305195385700_ref20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-3156.2006.01560.x","article-title":"Early determination of the reproduction number for vector-borne diseases: the case of dengue in Brazil","volume":"11","author":"Favier","year":"2006","journal-title":"Trop. Med. Int. Health"},{"key":"2021022305195385700_ref21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1126\/science.aaf9590","article-title":"Benefits and risks of the Sanofi-Pasteur dengue vaccine: modeling optimal deployment","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science"},{"key":"2021022305195385700_ref22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000617","article-title":"Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006","volume":"4","author":"Fried","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2021022305195385700_ref23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.4269\/ajtmh.2007.77.910","article-title":"Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences","volume":"77","author":"Gibbons","year":"2007","journal-title":"Amer. J. Trop. Med. Hyg."},{"key":"2021022305195385700_ref24","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"New Engl. J. Med."},{"key":"2021022305195385700_ref25","first-page":"1","article-title":"Dengue haemorrhagic fever\u2014a public health problem and a field for research","volume":"58","author":"Halstead","year":"1980","journal-title":"Bull. World Health Organ."},{"key":"2021022305195385700_ref26","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1111\/j.1749-6632.2009.05052.x","article-title":"Antibodies determine virulence in dengue","volume":"1171","author":"Halstead","year":"2009","journal-title":"Ann. New York Acad. Sci."},{"key":"2021022305195385700_ref27","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/infdis\/jiw340","article-title":"Critique of World Health Organization recommendation of a dengue vaccine","volume":"241","author":"Halstead","year":"2016","journal-title":"J. Inf. Dis. Perspectives"},{"key":"2021022305195385700_ref28","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.vaccine.2016.02.004","article-title":"Protective and immunological behaviour of chimeric yellow fever dengue vaccine","volume":"34","author":"Halstead","year":"2016","journal-title":"Vaccine"},{"key":"2021022305195385700_ref29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0025-5564(88)90111-3","article-title":"Optimal ages of vaccination for measles","volume":"89","author":"Hethcote","year":"1988","journal-title":"Math. Biosci."},{"key":"2021022305195385700_ref30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1574-695X.2010.00670.x","article-title":"Dengue in infants: an overview","volume":"59","author":"Jain","year":"2010","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"2021022305195385700_ref31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005653","article-title":"Tracking the return of Aedes Aegypti to Brazil, the major vector of the dengue, chikungunya and Zika viruses","volume":"11","author":"Kotsakiozi","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"2021022305195385700_ref32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.semdp.2007.07.002","article-title":"The pathology of dengue haemorrhagic fever","volume":"24","author":"Leong","year":"2007","journal-title":"Semin. Diagn. Pathol."},{"volume-title":"Determination of the optimal age to vaccinate against dengue using a tetravalent dengue vaccine in Brazil","year":"2019","author":"Maier","key":"2021022305195385700_ref33"},{"key":"2021022305195385700_ref34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mbs.2017.09.004","article-title":"Analysis of the optimal vaccination age for dengue in Brazil with a tetravalent dengue vaccine","volume":"294","author":"Maier","year":"2017","journal-title":"Math. Biosci."},{"key":"2021022305195385700_ref35","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1016\/j.vaccine.2017.06.004","article-title":"ADE and dengue vaccination","volume":"35","author":"Mart\u00ednez-Vega","year":"2017","journal-title":"Vaccine"},{"key":"2021022305195385700_ref36","first-page":"120","article-title":"Estimation of ${\\mathrm{R}}\\_0$ from the initial phase of an outbreak of a vector-borne infection","volume":"15","author":"Massad","year":"2010","journal-title":"Trop. Med. Int. Health"},{"key":"2021022305195385700_ref37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12889-019-6641-4","article-title":"30 years of fatal dengue cases in Brazil: a review","volume":"19","author":"Nunes","year":"2019","journal-title":"BMC Public Health"},{"volume-title":"Background paper on dengue vaccines","year":"2016","author":"SAGE Working Group on Dengue Vaccines & WHO Secretariat","key":"2021022305195385700_ref38"},{"volume-title":"Background paper on dengue vaccines\u2014revision of the background paper from 17 March 2016","year":"2018","author":"SAGE Working Group on Dengue Vaccines & WHO Secretariat","key":"2021022305195385700_ref39"},{"year":"2018","author":"Sanofi Pasteur Communication","key":"2021022305195385700_ref40"},{"year":"2015","author":"Sanofi Pasteur Press Release","key":"2021022305195385700_ref41"},{"year":"2016","author":"Sanofi Pasteur Press Release","key":"2021022305195385700_ref42"},{"year":"2016","author":"United States Central Intelligence Agency","key":"2021022305195385700_ref43"},{"key":"2021022305195385700_ref44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4269\/ajtmh.2011.11-0125","article-title":"Decay and persistence of maternal dengue antibodies among infants in Bangkok","volume":"85","author":"van Panhuis","year":"2011","journal-title":"Amer. Soc. Trop. Med. Hyg."},{"key":"2021022305195385700_ref45","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1093\/infdis\/jiw341","article-title":"Population perspectives and World Health Organization recommendations for CYD-TDV dengue vaccine","volume":"214","author":"Wilder-Smith","year":"2016","journal-title":"J. Inf. Dis."},{"volume-title":"Global strategy for dengue prevention and control 2012\u20132020","year":"2012","author":"World Health Organization","key":"2021022305195385700_ref46"},{"key":"2021022305195385700_ref47","first-page":"186","article-title":"The risk of dengue for non-immune foreign visitors to the 2016 summer Olympic Games in Rio de Janeiro Brazil","author":"Ximenes","year":"2016"}],"container-title":["Mathematical Medicine and Biology: A Journal of the IMA"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/imammb\/article-pdf\/38\/1\/1\/36337326\/dqaa007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/imammb\/article-pdf\/38\/1\/1\/36337326\/dqaa007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T07:27:35Z","timestamp":1723015655000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/imammb\/article\/38\/1\/1\/5863710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,7,16]]},"published-print":{"date-parts":[[2021,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/imammb\/dqaa007","relation":{},"ISSN":["1477-8599","1477-8602"],"issn-type":[{"type":"print","value":"1477-8599"},{"type":"electronic","value":"1477-8602"}],"subject":[],"published-other":{"date-parts":[[2021,3]]},"published":{"date-parts":[[2020,7,16]]}}}